Renal cell carcinoma antigen

Atkins, D., Ferrone, S., Schmahl, G. E., Storkel, S., and Seliger, B., 2004, Down-regulation of HLA class I antigen processing molecules an iimmme escape mechanism of renal cell carcinoma, / Urol. 171 885 889. 

Bukur, J., Malenica, B., Huber, G., and Seliger, B., 2003, Altered expression of nonclassical HLA class lb antigens in human renal cell carcinoma and its association with impaired immune response. Hum. Immunol 64 1081 1092. 

Unwin, R. D., Hamden, P., Pappin, D., Rahman, D., Whelan, P., Craven, R. A., et al. (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3,45-55. 

Kellner, R., Lichteneels, R., Atkins, D., Bukur,J., Ackermann, a.. Beck, J., Brenner, W., Melchior, S., Seliger, B. (2002). Targeting of tumor-associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2, 1743-1751. 

Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 22, 1801-1809. 

The mechanism by which IFN-a exerts antitumor activity is unclear, particularly in hematological cancers. In melanoma and renal cell carcinoma, antitumor effects may be mediated by augmented immune responses including activation of natural killer lymphocytes and enhanced expression of cell surface antigens (e.g., MHC I and II). However, these mechanisms have not been decisively proved. 

Antitumor responses have been observed with NMT in patients with renal cell carcinoma, melanoma, breast cancer, and other solid tumors. In order to improve on the efficacy seen with NMT, some investigators are evaluating novel approaches to enhance allogeneic immune responses against tumor-associated antigens (if available) such as posttransplant vaccination. 

Klade, C. S., Voss, T., Krystek, E., Ahorn, H., Zatloukal, K., Pummer, K., and Adolf, G. R. (2001) Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1, 890-898... 

Wieezorek TJ, Pinkus JL, Glickman JN, Pinkus GS. Gompari-son of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002 118 911-921. 

Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res. 1989 49 1802-1809. 

D2-40, a clone of podoplanin, is a recently developed commercially available antibody directed against the M2A antigen, a 40,000-kD sialoglycoprotein associated with germ cells and lymphatic endothelium. Chu and colleagues evaluated 53 cases of mesothelioma, 28 cases of reactive pleural tissue, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and 7 cases of urothelial carcinoma. The authors found D2-40 expression in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) reactive pleural tissues, and 17 of 26 (65%) ovarian serous carcinomas. They did not find D2-40 in the other tumors examined. The authors also observed that the neoplastic cells immunostained in a cell membrane distribution. 

Virtually all prostate carcinomas are positive for CAMS.2 and prostate-specific antigen. Prostate carcinomas frequent vertebrae more than CNS. Most renal cell carcinomas (RCCs) are positive for CAMS.2 and negative for CK20 a few are positive for CK7. TTF-1... 

TroVax immunotherapy for renal cell carcinoma consists of the gene for the 5T4 tumor-associated antigen, which is delivered to the body by means of a viral vector. This vaccine is currently undergoing phase III trials. 

---